# Exalys Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/exalys-therapeutics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.exalystx.com
- Total disclosed funding: $15M
- Latest round: Series A (Jul 16, 2020)
- Investors on record: 2

## About

Exalys Therapeutics, Inc. focuses on developing cutting-edge technology solutions that tackle complex challenges across various industries by enhancing data analytics and decision-making processes.Exalys Therapeutics, Inc. specializes in innovative solutions that improve operational efficiencies through advanced data analytics. The company is headquartered in San Diego, US. Rick Orr serves as the CEO. The company raised USD 15 mn in Series A funding on July 16, 2020, from investors Catalys Pacific and Domain Associates, marking a significant milestone in its funding journey.Exalys Therapeutics, Inc. specializes in offering innovative technology solutions designed to address various industry challenges. The core product offerings include advanced analytics platforms and decision-support tools aimed at enhancing operational efficiencies and enabling data-driven decision-making. These products are tailored for diverse sectors such as finance, healthcare, and logistics, providing end users with actionable insights to optimize their processes and drive strategic growth. The company primarily markets its products in North America and Europe, focusing on regions that are rapidly adopting digital transformation initiatives to stay competitive in their respective industries.The revenue model for Exalys Therapeutics, Inc. is structured around subscription-based services, enabling clients to access its suite of products while providing a steady flow of income to the company. Clients engage with the firm's analytics tools through tiered pricing plans that cater to various usage levels, allowing businesses to select the package that best fits their operational needs. Transactions are typically structured as annual or multi-year agreements, fostering long-term partnerships with clients. Flagship products offered by the company include its proprietary analytics platform, which delivers comprehensive insights into key performance indicators. This strategic approach ensures that Exalys Therapeutics, Inc. not only meets client expectations but also enhances customer loyalty through ongoing support and product updates.Exalys Therapeutics, Inc. plans to leverage its recent Series A funding of USD 15 mn raised in July 2020 to support the development of new products aimed at enhancing its analytics capabilities. The company targets expansion into European markets by the end of 2023, aiming to capitalize on increasing demand for advanced data solutions. The funding will also be allocated to marketing initiatives to increase visibility and establish partnerships in these new regions.

## Funding rounds

- Series A, Jul 16, 2020, $15M — Domain Associates, Catalys Pacific

## Investors

- Domain Associates (https://capitalatlas.ai/funds/domain-associates) — Series A
- Catalys Pacific (https://capitalatlas.ai/funds/catalys-pacific) — Series A